Research advances in diagnosis and treatment of hepatocellular carcinoma complicated by arterioportal shunt
Hepatocellular carcinoma (HCC) complicated by arterioportal shunt (APS) is commonly seen in clinical practice, with an incidence rate of 28.8%-63.2%. It is manifested as abdominal pain, diarrhea, and ascites and can also lead to serious complications of portal hypertension including gastrointestinal...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2017-02-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8023 |
| Summary: | Hepatocellular carcinoma (HCC) complicated by arterioportal shunt (APS) is commonly seen in clinical practice, with an incidence rate of 28.8%-63.2%. It is manifested as abdominal pain, diarrhea, and ascites and can also lead to serious complications of portal hypertension including gastrointestinal bleeding. Although there are various therapeutic methods, they tend to have poor clinical effects. APS is one of the most important causes of death in patients with HCC. This article introduces the etiology, typing, clinical manifestation, and therapies of HCC complicated by APS and points out that although there are various therapeutic methods for HCC complicated by APS, interventional treatment remains the most important method. The exploration of interventional treatment helps to improve patients′ prognosis. |
|---|---|
| ISSN: | 1001-5256 1001-5256 |